FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013905046> ?p ?o ?g. }

• W2013905046 endingPage "P272" @default.
• W2013905046 startingPage "P272" @default.
• W2013905046 abstract "Background And Aims: Rifaximin, a well tolerated,non absorbable,wide spectrum antibiotic,has a topical action without systemic effects. Aim of the study was to evaluate the efficacy of rifaximin, in a population of patients with mild to moderate left sided ulcerative colitis resistant to topic and oral 5ASA. Material And Methods: We enrolled 18 outpatients (10 F,8M, Mean age 45,4 y., range 22-71) from June 2001 through July 2003 with first attack or relapsing ulcerative colitis, ,without clinical and endoscopic signs of severe colitis, who failed to respond to a 2 weeks course of 5ASA 4.8 gr orally and 4 gr topically. The clinical activity of disease was defined in accordance with Truelove and Witts criteria. Colonoscopy was performed and endoscopic activity was defined in accordance with Baron criteria. All pts complained of >= 6 bowel movements with blood. Routine haematological and biochemical measurements were made at the beginning and after two weeks rifaximin therapy. Three pts had rectal involvement, 10 proctosigmoiditis, 5 left sided colitis. These pts instead of shifting to oral steroid treatment, as a rule, were offered a 2 weeks course of rifaximin 400 mg thrice daily plus 5ASA therapy. At end point pts were considered to be improved if they had =/< 3 bowel movements per day without blood. Pts improved were mantained with ongoing 5 ASA therapy and followed for a median of 13.7 months ( range4-27 ) to evaluate relapse rate. Colonoscopy was performed after 2 months and during flare-up. Results: Compliance was excellent and there was non significant changes in haematological and biochemical parameters. Overall 9 pts (50%) showed a positive response to treatment with <= 3 bowel movements without blood after 2 weeks, 3 experienced only reduction of bowel movements and amount of blood, 6 had no improvement or slight worsening. Out of patients clinically improved there were seven in stable, endoscopically proved , remission with standard oral and topic 5ASA during follow up, while there was a relapse in two, successfully treated with rifaximin at the same dosage but requiring steroids for a more effective disease control. Conclusion: High dosage rifaximin may be a safe ,valuable option in clinical practice in pts with mild-moderate left sided colitis who are or become resistant to 5ASA as we were able to manage 7 out 18 of these pts using rifaximin instead of steroids. In our experience rifaximin could be a useful bridge therapy to manage relapses before 5ASA become again clinically effective in maintenance treatment." @default.
• W2013905046 created "2016-06-24" @default.
• W2013905046 creator A5000761966 @default.
• W2013905046 creator A5023932706 @default.
• W2013905046 creator A5039152064 @default.
• W2013905046 creator A5086565105 @default.
• W2013905046 creator A5087625149 @default.
• W2013905046 date "2004-04-01" @default.
• W2013905046 modified "2023-10-14" @default.
• W2013905046 title "Rifaximin as Short-Term “Bridge Therapy” in Mild-Moderate Left Sided Colitis Resistant to 5 ASA." @default.
• W2013905046 doi "https://doi.org/10.1016/s0016-5107(04)01205-2" @default.
• W2013905046 hasPublicationYear "2004" @default.
• W2013905046 type Work @default.
• W2013905046 sameAs 2013905046 @default.
• W2013905046 citedByCount "0" @default.
• W2013905046 crossrefType "journal-article" @default.
• W2013905046 hasAuthorship W2013905046A5000761966 @default.
• W2013905046 hasAuthorship W2013905046A5023932706 @default.
• W2013905046 hasAuthorship W2013905046A5039152064 @default.
• W2013905046 hasAuthorship W2013905046A5086565105 @default.
• W2013905046 hasAuthorship W2013905046A5087625149 @default.
• W2013905046 hasConcept C121608353 @default.
• W2013905046 hasConcept C126322002 @default.
• W2013905046 hasConcept C141071460 @default.
• W2013905046 hasConcept C2775862500 @default.
• W2013905046 hasConcept C2778260677 @default.
• W2013905046 hasConcept C2778435480 @default.
• W2013905046 hasConcept C2778889925 @default.
• W2013905046 hasConcept C2779134260 @default.
• W2013905046 hasConcept C2780479503 @default.
• W2013905046 hasConcept C2908647359 @default.
• W2013905046 hasConcept C501593827 @default.
• W2013905046 hasConcept C526805850 @default.
• W2013905046 hasConcept C71924100 @default.
• W2013905046 hasConcept C86803240 @default.
• W2013905046 hasConcept C89423630 @default.
• W2013905046 hasConcept C90924648 @default.
• W2013905046 hasConcept C99454951 @default.
• W2013905046 hasConceptScore W2013905046C121608353 @default.
• W2013905046 hasConceptScore W2013905046C126322002 @default.
• W2013905046 hasConceptScore W2013905046C141071460 @default.
• W2013905046 hasConceptScore W2013905046C2775862500 @default.
• W2013905046 hasConceptScore W2013905046C2778260677 @default.
• W2013905046 hasConceptScore W2013905046C2778435480 @default.
• W2013905046 hasConceptScore W2013905046C2778889925 @default.
• W2013905046 hasConceptScore W2013905046C2779134260 @default.
• W2013905046 hasConceptScore W2013905046C2780479503 @default.
• W2013905046 hasConceptScore W2013905046C2908647359 @default.
• W2013905046 hasConceptScore W2013905046C501593827 @default.
• W2013905046 hasConceptScore W2013905046C526805850 @default.
• W2013905046 hasConceptScore W2013905046C71924100 @default.
• W2013905046 hasConceptScore W2013905046C86803240 @default.
• W2013905046 hasConceptScore W2013905046C89423630 @default.
• W2013905046 hasConceptScore W2013905046C90924648 @default.
• W2013905046 hasConceptScore W2013905046C99454951 @default.
• W2013905046 hasIssue "5" @default.
• W2013905046 hasLocation W20139050461 @default.
• W2013905046 hasOpenAccess W2013905046 @default.
• W2013905046 hasPrimaryLocation W20139050461 @default.
• W2013905046 hasRelatedWork W1975032444 @default.
• W2013905046 hasRelatedWork W2049047934 @default.
• W2013905046 hasRelatedWork W2105447106 @default.
• W2013905046 hasRelatedWork W2326791703 @default.
• W2013905046 hasRelatedWork W2331780948 @default.
• W2013905046 hasRelatedWork W2765902450 @default.
• W2013905046 hasRelatedWork W2922011006 @default.
• W2013905046 hasRelatedWork W2963825579 @default.
• W2013905046 hasRelatedWork W2999446179 @default.
• W2013905046 hasRelatedWork W74726072 @default.
• W2013905046 hasVolume "59" @default.
• W2013905046 isParatext "false" @default.
• W2013905046 isRetracted "false" @default.
• W2013905046 magId "2013905046" @default.
• W2013905046 workType "article" @default.